Cambridge Medical Robotics, a company that is designing a robotic system for minimal access surgery, has raised up to $26 million in its Series A funding round. The investment adds up with the first tranche in July 2016 making it a total of $46 million. According to CMR, the investment will equip them to build on recent tests of its device on cadavers.

The Series A investment came from previous investors including Cambridge Innovation International, Escala Capital, LGT Global Invest, ABB Ventures as well as a new investor Watrium. The recent investment came fourteen months after the existing supporters invested up to $20 million into the startup now making it a total of $46 million.

Cambridge Medical Robotics says it will use the proceeds to push its surgical robotic device, Versius, through continuous validation studies and to commence production of further robotic systems. The company is also working towards regulatory approval and commercialization.

Versius is a compact robotic arm that features a four-axis joint specifically designed to mimic the dexterity of the human wrist and consequently hold surgical instruments the way surgeons do. This simply means that Versius could be used across an extensive range of minimal access procedures while maintaining its impressive compact and portable form.

If the system works as planned, it could help solve some of the problems that affect the short and long-term capacities of surgeons. For the most part, surgeons who perform minimal access surgery are likely to suffer from fatigue that limits the amount of time spent on these procedures. Moreover, the long-term issues such as repetitive strain injuries and other severe issues like neck problems and chronic back pain can cause surgeons to cut their careers short.

This is precisely where the Versius come into play. CMR believes the robotic arm lessen these problems by giving surgeons the chance to perform minimal access procedures with ease and comfort. It’s also good to point out that the MedTech startup has designed a virtual environment as well as a training program to teach surgeons how to use the device properly. All these initiatives will go live if the startup can commercialize Versius.

Cambridge Medical Robotics has completed the most recent set of cadaver trials, demonstrating the robot’s ability to perform pelvic, upper gastrointestinal, gynecological, colorectal and renal surgery. These studies are moving CMR closer and closer to first-in-human trials.

“Versius continues to demonstrate its leading position in this next generation of robotic surgery systems,” says Martin Frost, Chief Executive Officer of CMR.

He also adds, “I’m pleased to report this significant progress and thank our existing and new investors for their enthusiastic support and look forward to continuing our rapid development as we lay the foundations for producing and marketing this in-demand system.”